Anna Galkin

Company: Axelia Oncology

Job title: Chief Scientific Officer

Seminars:

Developing a Systemically Delivered TLR2 Agonist for Cancer Immunotherapy 3:30 pm

Understand the mechanistic rationale for pursuing TLR2 agonists in CPI resistant solid tumor indications Review the safety and tolerability profile of AXA-042 demonstrated in the first-in-human clinical trial Translational lessons from the clinic: impact of TLR2 target engagement on clinical safety and response biomarkers Read more

day: Conference Day 2